OMS906
- Generic Name
- OMS906
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
Phase 2
Active, not recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05972967
- Locations
- 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath